Evidence map›Paper›PMID 33785525›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2021

Brain Concentrations of Methylone and Its Metabolites after Systemic Methylone Administration: Relationship to Pharmacodynamic Effects.

Nicole Centazzo, Michael R Chojnacki, Joshua S Elmore, Raider Rodriguez, Teeshavi Acosta, Masaki Suzuki, Kenner C Rice, Michael H Baumann, Marta Concheiro

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Synthetic Cathinones and Neurotoxicity Risks: A Systematic Review.International journal of molecular sciences · 2023
    Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Nicole CentazzoDepartment of Sciences, John Jay College of Criminal Justice, City University of New York, New York, New York (N.C., R.R., T.A., M.C.); Designer Drug Research Unit, Intramural Research Program (IRP), National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH), Baltimore, Maryland (M.R.C., J.S.E., M.H.B.); and Drug Design and Synthesis Section, IRP, NIDA, NIH, Rockville, Maryland (M.S., K.C.R.).
Michael R ChojnackiDepartment of Sciences, John Jay College of Criminal Justice, City University of New York, New York, New York (N.C., R.R., T.A., M.C.); Designer Drug Research Unit, Intramural Research Program (IRP), National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH), Baltimore, Maryland (M.R.C., J.S.E., M.H.B.); and Drug Design and Synthesis Section, IRP, NIDA, NIH, Rockville, Maryland (M.S., K.C.R.).
Joshua S ElmoreDepartment of Sciences, John Jay College of Criminal Justice, City University of New York, New York, New York (N.C., R.R., T.A., M.C.); Designer Drug Research Unit, Intramural Research Program (IRP), National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH), Baltimore, Maryland (M.R.C., J.S.E., M.H.B.); and Drug Design and Synthesis Section, IRP, NIDA, NIH, Rockville, Maryland (M.S., K.C.R.).
Raider RodriguezDepartment of Sciences, John Jay College of Criminal Justice, City University of New York, New York, New York (N.C., R.R., T.A., M.C.); Designer Drug Research Unit, Intramural Research Program (IRP), National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH), Baltimore, Maryland (M.R.C., J.S.E., M.H.B.); and Drug Design and Synthesis Section, IRP, NIDA, NIH, Rockville, Maryland (M.S., K.C.R.).
Teeshavi AcostaDepartment of Sciences, John Jay College of Criminal Justice, City University of New York, New York, New York (N.C., R.R., T.A., M.C.); Designer Drug Research Unit, Intramural Research Program (IRP), National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH), Baltimore, Maryland (M.R.C., J.S.E., M.H.B.); and Drug Design and Synthesis Section, IRP, NIDA, NIH, Rockville, Maryland (M.S., K.C.R.).
Masaki SuzukiDepartment of Sciences, John Jay College of Criminal Justice, City University of New York, New York, New York (N.C., R.R., T.A., M.C.); Designer Drug Research Unit, Intramural Research Program (IRP), National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH), Baltimore, Maryland (M.R.C., J.S.E., M.H.B.); and Drug Design and Synthesis Section, IRP, NIDA, NIH, Rockville, Maryland (M.S., K.C.R.).
Kenner C RiceDepartment of Sciences, John Jay College of Criminal Justice, City University of New York, New York, New York (N.C., R.R., T.A., M.C.); Designer Drug Research Unit, Intramural Research Program (IRP), National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH), Baltimore, Maryland (M.R.C., J.S.E., M.H.B.); and Drug Design and Synthesis Section, IRP, NIDA, NIH, Rockville, Maryland (M.S., K.C.R.).ORCID 0000-0002-1147-9147
Michael H BaumannDepartment of Sciences, John Jay College of Criminal Justice, City University of New York, New York, New York (N.C., R.R., T.A., M.C.); Designer Drug Research Unit, Intramural Research Program (IRP), National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH), Baltimore, Maryland (M.R.C., J.S.E., M.H.B.); and Drug Design and Synthesis Section, IRP, NIDA, NIH, Rockville, Maryland (M.S., K.C.R.) mbaumann@mail.nih.gov mconcheiro-guisan@jjay.cuny.edu.
Marta ConcheiroDepartment of Sciences, John Jay College of Criminal Justice, City University of New York, New York, New York (N.C., R.R., T.A., M.C.); Designer Drug Research Unit, Intramural Research Program (IRP), National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH), Baltimore, Maryland (M.R.C., J.S.E., M.H.B.); and Drug Design and Synthesis Section, IRP, NIDA, NIH, Rockville, Maryland (M.S., K.C.R.) mbaumann@mail.nih.gov mconcheiro-guisan@jjay.cuny.edu.ORCID 0000-0002-3858-1280
National Institutes of Health · US

Funding

Medicinal Chemistry of Drugs Acting on Central and Peripheral Opioid ReceptorsZIADA000527 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI RICE, KENNER · 2009 to 2025
$23.2M
Studies on MDMA and Related CompoundsZIADA000523 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI BAUMANN, MICHAEL · 2009 to 2025
$16.4M
IMPROVING HEALTH CARE UTILIZATION IN HIV+ DRUG USERSK23DA000523 · NIDA · JOHNS HOPKINS UNIVERSITY · PI GEBO, KELLY A · 2001 to 2005
$794k
Studies on MDMA and Related CompoundsZ01DA000523 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI ROTHMAN, RICHARD · 2008 to 2008
$199k
Intramural NIH HHS Z01 DA000523NIDA NIH HHS K23 DA000523
6 · The paper itself

Abstract

3,4-Methylenedioxy-

Indexed as

BrainMethamphetamineRats, Sprague-DawleyAnimalsDose-Response Relationship, DrugMaleMotor ActivityRatsMethamphetaminemethylone

Identifiers

PMID33785525
PMCPMC11058058
OpenAlexW3147805955

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.